A study on B-cell NHL demonstrated that PD-L1 expression was confined to a subset of DLBCL with activated B-cell features, which carries a poorer prognosis and frequently recurs after conventional chemoimmunotherapy (9). This evidence concerns the gene CD274 and diffuse large B-cell lymphoma.